Welcome to our dedicated page for Zenas BioPharma SEC filings (Ticker: ZBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of pages on immunology pathways, trial endpoints, and non-cash R&D charges make Zenas BioPharma filings tough to navigate. If you have ever searched for Zenas BioPharma SEC filings explained simply or wondered how insider grants line up with pivotal data releases, you know the challenge.
Stock Titan solves it. Our AI digests every document the moment it appears on EDGAR, then delivers side-by-side summaries and red-flag alerts. Whether you need a Zenas BioPharma quarterly earnings report 10-Q filing breakdown or want Zenas BioPharma Form 4 insider transactions real-time, the platform surfaces what matters in seconds. Key filing types include:
- 10-K & 10-Q: Cash runway, R&D spend, pipeline milestones—see the Zenas BioPharma annual report 10-K simplified next to our cash-burn tracker.
- 8-K: Trial readouts, licensing deals, financing—get Zenas BioPharma 8-K material events explained in plain language.
- Form 4: Monitor Zenas BioPharma executive stock transactions Form 4 and spot buying or selling trends.
- DEF 14A: See the Zenas BioPharma proxy statement executive compensation section without scrolling through exhibits.
Our AI-powered summaries highlight how obexelimab’s CD19/FcγRIIb approach impacts risk factors, flag dilution triggers in shelf registrations, and link trial progress to valuation. Use the tools to conduct Zenas BioPharma earnings report filing analysis, set alerts for Zenas BioPharma insider trading Form 4 transactions, and streamline due diligence. If you are understanding Zenas BioPharma SEC documents with AI, the work is already done—updated in real time, organized by relevance, and always one click away.
Zenas BioPharma is registering 762,000 shares of its common stock to cover inducement stock option grants made to three employees under the employment inducement exemption of Nasdaq Rule 5635(c)(4). The filing omits Part I prospectus text under Rule 428(a) and confirms that the omitted documents will be delivered to the option recipients and that certain company reports are incorporated by reference, including the company’s annual report for the fiscal year ended December 31, 2024 and subsequent quarterly reports.
The filing discloses corporate governance protections: elimination of director liability to the extent permitted by DGCL Section 102(b)(7), indemnification powers under DGCL Section 145, indemnification agreements with directors and officers providing broader rights than statute, and directors� and officers� liability insurance. Exhibits include the Form of Inducement Option Award Agreement, the 2024 Equity Incentive Plan, counsel opinion and auditor consents.
Zenas BioPharma (ZBIO) reported a net loss of $52.2 million for the quarter and $85.8 million for the six months ended June 30, 2025, driven by higher research and development and general and administrative spending. Research and development expense was $43.0 million for the quarter versus $33.8 million a year earlier; total operating expenses for the quarter were $55.2 million. Revenue recognized was $10.0 million for the six months (sublicense with Zai), and no revenue was recognized in the quarter.
The company held $274.9 million of cash, cash equivalents and investments as of June 30, 2025 and management expects these resources to fund operations into the fourth quarter of 2026. Total assets were $293.1 million, total liabilities $53.5 million, and stockholders' equity $239.6 million. Accumulated deficit reached $473.2 million. Material agreements disclosed include a $50.0 million upfront payment from BMS and a $10.0 million upfront payment from Zai recognized in the period.
FAQ
What is the current stock price of Zenas BioPharma (ZBIO)?
What is the market cap of Zenas BioPharma (ZBIO)?
